• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CYP2C9 相互作用药物对华法林药物基因组学的影响。

Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.

机构信息

Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Graduate Program in Genetic Counseling, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

出版信息

Clin Transl Sci. 2020 Sep;13(5):941-949. doi: 10.1111/cts.12781. Epub 2020 Apr 9.

DOI:10.1111/cts.12781
PMID:32270628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7485961/
Abstract

Precise dosing of warfarin is important to achieve therapeutic benefit without adverse effects. Pharmacogenomics explains some interindividual variability in warfarin response, but less attention has been paid to drug-drug interactions in the context of genetic factors. We investigated retrospectively the combined effects of cytochrome P450 (CYP)2C9 and vitamin K epoxide reductase complex (VKORC)1 genotypes and concurrent exposure to CYP2C9-interacting drugs on long-term measures of warfarin anticoagulation. Study participants predicted to be sensitive responders to warfarin based on CYP2C9 and VKORC1 genotypes, had significantly greater international normalized ratio (INR) variability over time. Participants who were concurrently taking CYP2C9-interacting drugs were found to have greater INR variability and lesser time in therapeutic range. The associations of INR variability with genotype were driven by the subgroup not exposed to interacting drugs, whereas the effect of interacting drug exposure was driven by the subgroup categorized as normal responders. Our findings emphasize the importance of considering drug interactions in pharmacogenomic studies.

摘要

华法林的精确剂量对于在没有不良反应的情况下达到治疗效果很重要。药物基因组学解释了华法林反应中一些个体间的差异,但在遗传因素的背景下,药物-药物相互作用的关注较少。我们回顾性研究了细胞色素 P450(CYP)2C9 和维生素 K 环氧化物还原酶复合物(VKORC)1 基因型与同时暴露于 CYP2C9 相互作用药物对长期华法林抗凝的联合影响。根据 CYP2C9 和 VKORC1 基因型预测对华法林敏感的研究参与者,其国际标准化比值(INR)随时间的变化具有显著更大的可变性。同时服用 CYP2C9 相互作用药物的参与者发现 INR 可变性更大,治疗范围的时间更少。INR 可变性与基因型的关联主要归因于未暴露于相互作用药物的亚组,而相互作用药物暴露的影响则归因于正常反应者亚组。我们的研究结果强调了在药物基因组学研究中考虑药物相互作用的重要性。

相似文献

1
Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.CYP2C9 相互作用药物对华法林药物基因组学的影响。
Clin Transl Sci. 2020 Sep;13(5):941-949. doi: 10.1111/cts.12781. Epub 2020 Apr 9.
2
A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.CYP2C9、CYP2C9 联合 VKORC1 及 CYP2C9 联合 VKORC1 和 CYP4F2 基因型指导的华法林剂量策略与传统策略相比的网络荟萃分析。
J Clin Pharm Ther. 2021 Jun;46(3):640-648. doi: 10.1111/jcpt.13334. Epub 2020 Dec 21.
3
Pharmacogenetics of Warfarin in a Diverse Patient Population.华法林在不同患者人群中的药物遗传学。
J Cardiovasc Pharmacol Ther. 2019 Nov;24(6):521-533. doi: 10.1177/1074248419843530. Epub 2019 May 7.
4
Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.CYP2C9、VKORC1 和 CYP4F2 多态性对华法林药效学参数的影响:一项横断面研究。
Pharmacol Rep. 2021 Oct;73(5):1405-1417. doi: 10.1007/s43440-021-00256-w. Epub 2021 Apr 3.
5
Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.心房颤动合并瓣膜置换患者不同CYP2C9和VKORC1基因型对华法林剂量的需求。
Int J Clin Pharmacol Ther. 2017 Feb;55(2):126-132. doi: 10.5414/CP202494.
6
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.机械心脏瓣膜患者尿苷二磷酸葡萄糖醛酸转移酶多态性对稳定华法林剂量的影响。
Cardiovasc Ther. 2015 Dec;33(6):324-8. doi: 10.1111/1755-5922.12147.
7
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.影响心房颤动抗凝控制质量和血管事件的遗传与非遗传因素
J Stroke Cerebrovasc Dis. 2017 Jun;26(6):1383-1390. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.022. Epub 2017 Apr 12.
8
CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.CYP2C9 和 VKORC1 基因分型在俄罗斯患者长期华法林治疗中的作用。
Pharmacogenomics J. 2020 Oct;20(5):687-694. doi: 10.1038/s41397-020-0157-2. Epub 2020 Feb 6.
9
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.VKORC1 和 CYP2C9 基因型是儿童华法林相关结局的预测因子。
Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.
10
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.细胞色素P450同工酶CYP2C9和维生素K环氧化物还原酶复合体亚基1的基因型共同决定华法林稳定剂量:一项前瞻性研究。
J Thromb Thrombolysis. 2006 Dec;22(3):191-7. doi: 10.1007/s11239-006-9030-7.

引用本文的文献

1
Unveiling the impact of water-boiled cannabis on warfarin: A case report of atrial fibrillation patients after cannabis legalization in Thailand.揭示水煮大麻对华法林的影响:泰国大麻合法化后房颤患者的病例报告
Toxicol Rep. 2024 Nov 28;13:101838. doi: 10.1016/j.toxrep.2024.101838. eCollection 2024 Dec.
2
Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.心脏瓣膜置换术后患者基因多态性与华法林初始治疗的相关性
Pharmacol Rep. 2024 Apr;76(2):390-399. doi: 10.1007/s43440-024-00575-8. Epub 2024 Mar 8.
3
A super-geriatric patient with gastrostomy underwent life-threatening prothrombin time-international normalized ratio prolongation by warfarin following fasting and antibiotic therapy.

本文引用的文献

1
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.非洲裔患者华法林相关出血与遗传变异的关联。
JAMA. 2018 Oct 23;320(16):1670-1677. doi: 10.1001/jama.2018.14955.
2
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.静脉血栓栓塞症患者对华法林和依度沙班的遗传学及临床反应
Heart. 2017 Nov;103(22):1800-1805. doi: 10.1136/heartjnl-2016-310901. Epub 2017 Jul 8.
3
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
一名接受胃造口术的超高龄患者在禁食和抗生素治疗后,因华法林导致凝血酶原时间-国际标准化比值延长,危及生命。
Clin Case Rep. 2023 Sep 3;11(9):e7762. doi: 10.1002/ccr3.7762. eCollection 2023 Sep.
4
Relationship between elevated bilirubin levels and enhanced warfarin effects during biliary obstruction.胆道梗阻期间胆红素水平升高与华法林作用增强之间的关系。
Eur J Clin Pharmacol. 2023 Mar;79(3):437-443. doi: 10.1007/s00228-023-03459-7. Epub 2023 Feb 1.
5
Drug Interactions Affecting Oral Anticoagulant Use.药物相互作用对口服抗凝药物使用的影响。
Circ Arrhythm Electrophysiol. 2022 Jun;15(6):e007956. doi: 10.1161/CIRCEP.121.007956. Epub 2022 May 27.
6
Does cumulative topical antibiotic powder use increase the risk of drug induced acute kidney injury in fracture patients?骨折患者累积使用外用抗生素粉剂会增加药物性急性肾损伤的风险吗?
Bone Jt Open. 2022 Apr;3(4):284-290. doi: 10.1302/2633-1462.34.BJO-2022-0009.R1.
临床药物基因组学实施联盟(CPIC)华法林给药的药物基因组学指导原则:2017年更新版
Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.
4
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.华法林药物遗传学给药在实际临床应用中的抗凝终点:一种新的药物遗传学给药方法建议
Clin Pharmacol Ther. 2017 May;101(5):675-683. doi: 10.1002/cpt.558. Epub 2016 Dec 29.
5
Genetic determinants of variability in warfarin response after the dose-titration phase.剂量滴定阶段后华法林反应变异性的遗传决定因素。
Pharmacogenet Genomics. 2016 Nov;26(11):510-516. doi: 10.1097/FPC.0000000000000244.
6
Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.82个药物代谢基因的遗传变异:来自eMERGE网络的PGRNseq数据。
Clin Pharmacol Ther. 2016 Aug;100(2):160-9. doi: 10.1002/cpt.350. Epub 2016 Jun 1.
7
National Trends in Ambulatory Oral Anticoagulant Use.门诊口服抗凝剂使用的全国趋势。
Am J Med. 2015 Dec;128(12):1300-5.e2. doi: 10.1016/j.amjmed.2015.05.044. Epub 2015 Jul 2.
8
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.基因与华法林和依度沙班的临床应答:来自随机、双盲、ENGAGE AF-TIMI 48 试验的结果。
Lancet. 2015 Jun 6;385(9984):2280-7. doi: 10.1016/S0140-6736(14)61994-2. Epub 2015 Mar 11.
9
Addressing phenoconversion: the Achilles' heel of personalized medicine.应对表型转换:个性化医疗的致命弱点。
Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441.
10
A randomized trial of genotype-guided dosing of warfarin.华法林基因指导剂量的随机试验。
N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.